Home › Anaplastic Large-Cell Lymphoma › New York
Anaplastic Large-Cell Lymphoma clinical trials in New York
5 studies for Anaplastic Large-Cell Lymphoma are looking for participants at sites in New York.
Cities in New York
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medicine, New York
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06561048Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- University of Rochester, Rochester
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 14, 2026 · NCT06724237A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated May 26, 2026 · NCT07001384Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
- New York Medical College, Valhalla
RecruitingPhase 2
Ages 1 to 39 · All sexes · Updated May 20, 2026 · NCT07013565A Registry for People With T-cell Lymphoma
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities), Commack
- Memorial Sloan Kettering Westchester (All protocol activities), Harrison
- Weill Cornell Medical Center (Data Collection Only), New York
- and 2 more
RecruitingObservational study
All ages · All sexes · Updated May 20, 2026 · NCT05978141From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.